Acta Scientific MICROBIOLOGY (ISSN: 2581-3226)

Editorial Volume 4 Issue 8

Mucormycosis: Current Update in Pandemic COVID-19

Anish Khan1*, Aishwarya Soni2 and Amit Kumar3

1Centre for Biotechnology, Maharshi Dayanand University, Rohtak-124001, Haryana, India
2Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology-Murthal, Sonepat-131039, Haryana, India
3Assistant Professor, Head of the Department of Zoology, Government College for Women, Gohana-131301, Sonepat, Haryana, India

*Corresponding Author: Anish Khan, Centre for Biotechnology, Maharshi Dayanand University, India. Email: anishkhan9991@gmail.com

Received: June 10, 2021; Published: July 01, 2021

Background

  Corona virus disease-2019 (COVID-19) is a pandemic entity caused by a novel corona virus (severe acute respiratory syndrome-coronavirus-2; SARS-CoV-2), which was firstly documented in Wuhan, Hubei territory in China on December 2019 [1,2]. SARS-CoV-2 is continuing to spread worldwide to till date with a high proportion of infected or affecting ≥10 million individuals globally [1]. Until now, there is no permanent cure for pandemic COVID-19 disease, though a variety of executive options have been evaluated and managed with systemic glucocorticoids for recovery of endurance rate of COVID-19 patients [2]. However, an array of complications reported during and post COVID-19 infection due to extensive use of glucocorticoids, which can lead to secondary fungal co-infection [1,2].

References

  1. Sarkar S., et al. "COVID-19 and orbital mucormycosis”. Indian Journal of Ophthalmology4 (2021): 1002.
  2. Garg D., et al. "Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature”. Mycopathologia (2021): 1-10
  3. Prabhu RM and Robin P. "Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment”. Clinical Microbiology and Infection 10 (2004): 31-47.
  4. Skiada A., et al. "Challenges in the diagnosis and treatment of mucormycosis”. Medical Mycology 56 (2018): S93-S101.
  5. Jestin M., et al. "Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study”. Annals of Intensive Care1 (2021): 1-8.
  6. Millon L., et al. "Molecular strategies to diagnose mucormycosis”. Journal of Fungi1 (2019): 24.
  7. Dadwal SS and Dimitrios PK. "Recent advances in the molecular diagnosis of mucormycosis”. Expert review of Molecular Diagnostics10 (2018): 845-854.
  8. Jeong W., et al. "The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports”. Clinical Microbiology and Infection1 (2019): 26-34.
  9. Lackner M., et al. "Laboratory diagnosis of mucormycosis: current status and future perspectives”. Future Microbiology5 (2014): 683-695.
  10. Kidd SE, et al. "A new age in molecular diagnostics for invasive fungal disease: are we ready?". Frontiers in Microbiology 10 (2020): 2903.

Citation

Citation: Anish Khan., et al. “Mucormycosis: Current Update in Pandemic COVID-19". Acta Scientific Microbiology 4.8 (2021): 01-02.

Copyright

Copyright: © 2021 Anish Khan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US